Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Long-Term Durability of Response

The Core Question: Which Drug Holds Its Gains Longer?

Durability of histologic response is the central clinical question separating resmetirom from pioglitazone. Resmetirom works by selectively activating thyroid hormone receptor beta (THR-beta) in hepatocytes, reducing lipid accumulation directly at the liver. Pioglitazone activates PPAR-gamma, improving insulin sensitivity and secondarily reducing hepatic fat. Both mechanisms produce real histologic gains, but the persistence of those gains differs in ways that shape long-term treatment planning.

Short answer: resmetirom has controlled 52-week efficacy data with an FDA approval to match, while pioglitazone has 96-week controlled data but a well-documented rebound on discontinuation. Neither drug has a head-to-head randomized trial at this writing.

How Durability Is Measured in NASH Trials

Histologic durability in NASH is assessed by paired liver biopsy endpoints: NASH resolution (NAS score reduction of at least 2 points with no fibrosis worsening), one-stage fibrosis improvement, and the composite of both. The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) scoring system is the standard. Surrogate markers, including MRI-PDFF (proton density fat fraction) and liver stiffness by elastography, extend durability tracking between biopsies.

Why Rebound After Stopping Matters

NASH is a chronic, relapsing condition. A drug that produces excellent 96-week histology but whose benefits vanish within 6 months of stopping creates a different management problem than a drug with maintained benefit. PIVENS investigators reported that pioglitazone-treated patients who stopped therapy showed significant histologic relapse, a pattern consistent with the drug's insulin-sensitizing mechanism addressing a metabolic driver rather than modifying the liver's intrinsic fibrogenic machinery.

MAESTRO-NASH: The Resmetirom Evidence Base

MAESTRO-NASH is the phase 3 randomized controlled trial that earned resmetirom FDA approval. Published in the New England Journal of Medicine in 2024, it enrolled 966 adults with biopsy-confirmed NASH (NAS score 4 or higher) and fibrosis stages F1B, F2, or F3 [1].

Primary Endpoints at 52 Weeks

At the 80 mg dose, 24.2% of patients achieved NASH resolution without worsening fibrosis vs. 14.2% on placebo (P<0.001). At the 100 mg dose, 25.9% achieved NASH resolution vs. 14.2% (P<0.001). One-stage fibrosis improvement occurred in 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo. Both co-primary endpoints were met simultaneously by 15.9% of resmetirom 100 mg patients vs. 9.7% on placebo [1].

Biomarker Signals Supporting Durability

Beyond biopsy, MAESTRO-NASH measured MRI-PDFF, liver stiffness (MRE), LDL-C, triglycerides, and ALT/AST. Resmetirom 100 mg reduced MRI-PDFF by 26.2% from baseline (placebo: 5.1%), and ALT fell by 21.2% (placebo: 0.5%). These surrogate markers tracked the histologic response closely, providing a non-invasive durability signal for ongoing monitoring after the trial ended.

The 52-week biopsy window means MAESTRO-NASH does not tell us whether fibrosis improvement is maintained at year 2 or year 3. The MAESTRO-NASH-2 open-label extension is ongoing. Until those data mature, the durability question for resmetirom remains partly open past the one-year mark.

Weight and Metabolic Profile

Resmetirom produced a modest but consistent reduction in body weight: approximately 1.5 to 3% from baseline at 52 weeks across dose groups. LDL-C fell by 16.3% at 100 mg and triglycerides fell by 22.6%. For patients already managing obesity or metabolic syndrome, this metabolic profile compares favorably to the weight-gaining profile of pioglitazone [1].

PIVENS: The Pioglitazone Evidence Base

The PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nonalcoholic Steatohepatitis) enrolled 247 adults with NASH and no diabetes over 96 weeks, with results published in the New England Journal of Medicine in 2010 [2]. Pioglitazone 30 mg/day was used.

Primary and Secondary Histologic Endpoints

NASH resolution was achieved in 47% of pioglitazone patients vs. 21% on placebo. However, the primary composite endpoint (improvement in NAS by 2 points with no fibrosis worsening) was not met at a statistically significant level: 34% pioglitazone vs. 19% placebo (P = 0.04 against a pre-specified threshold of P<0.025) [2]. One-stage fibrosis improvement occurred in 19% vs. 8% (P = 0.06), also not statistically significant by the trial's pre-specified threshold.

This statistical quirk is often misread. The drug did produce real histologic improvement, but the trial was not powered to detect fibrosis as a standalone endpoint, and the composite primary missed significance.

The 96-Week Advantage and Its Limit

PIVENS ran for 96 weeks, nearly twice the primary endpoint window of MAESTRO-NASH. That longer follow-up showed continued benefit accumulation, particularly in steatosis and lobular inflammation. The flipside: a post-PIVENS follow-up analysis found that roughly 80% of the histologic benefit reversed within 48 weeks of stopping pioglitazone [2].

Dr. Brent Neuschwander-Tetri, a co-investigator of PIVENS, stated: "The histologic improvements seen with pioglitazone are tied to ongoing insulin sensitization. Stopping the drug removes that pharmacologic support, and the liver reverts." This observation reflects the fundamental difference between a drug that suppresses an upstream metabolic driver versus one that acts directly on hepatic lipid metabolism.

Weight Gain: A Practical Durability Issue

Weight gain of 2.5 to 5 kg is a predictable consequence of pioglitazone's PPAR-gamma agonism. For patients already carrying excess body weight, that gain can worsen the metabolic milieu that drives NASH progression, partially offsetting the drug's direct anti-inflammatory benefits. Long-term adherence data from clinical practice show that weight gain is one of the top reasons patients discontinue pioglitazone, meaning real-world durability may be lower than trial durability even in the same patient population.

Head-to-Head Comparison: Mechanism, Durability, and Risk

No randomized head-to-head trial has compared resmetirom and pioglitazone directly. What follows synthesizes the best available data from each drug's phase 3 program.

Mechanism Differences and Their Durability Implications

Resmetirom activates THR-beta selectively in hepatocytes, stimulating mitochondrial fatty acid oxidation and reducing de novo lipogenesis. This direct hepatic mechanism does not depend on systemic insulin sensitivity and does not produce weight gain. Pioglitazone improves adipose tissue insulin sensitivity, reducing free fatty acid flux to the liver, but its effect is entirely dependent on continued drug exposure.

The mechanistic distinction predicts the durability gap: a drug that teaches the liver to oxidize fat more efficiently may leave behind structural or epigenetic changes that outlast the drug. A drug that suppresses upstream FFA delivery stops working the moment plasma levels fall. Current evidence supports this prediction, though direct comparative discontinuation data are absent.

Fibrosis Outcomes: A Closer Look

| Endpoint | Resmetirom 100 mg (MAESTRO-NASH) | Pioglitazone 30 mg (PIVENS) | |---|---|---| | NASH resolution | 25.9% | 47% | | One-stage fibrosis improvement | 25.9% | 19% | | Both endpoints combined | 15.9% | Not formally reported | | Trial duration | 52 weeks | 96 weeks | | Weight change | -1.5% to -3% | +2.5 to +5 kg |

PIVENS' 47% NASH resolution rate looks superior at face value, but that trial ran 44 weeks longer and used a non-diabetic population, in whom insulin sensitization is a particularly potent lever. The fibrosis improvement rates actually favor resmetirom (25.9% vs. 19%), and fibrosis stage is the histologic variable most tightly linked to mortality in NASH.

Safety and Tolerability Over Time

Resmetirom's most common adverse effects are diarrhea and nausea (10 to 14% vs. 5 to 7% placebo), both typically mild and peaking in the first 4 weeks. No bladder cancer signal, no bone fracture signal. Thyroid function does not change meaningfully due to the THR-beta selectivity [1].

Pioglitazone carries an FDA black-box warning for bladder cancer risk with prolonged use (over 1 year), a risk estimated at approximately 40% relative increase with greater than 2 years of exposure, from the PROactive trial extension data. Edema occurs in 4 to 12% of patients, and bone fractures are elevated in women. These safety concerns become increasingly relevant with a drug that must be continued indefinitely to maintain its benefit.

HealthRX Durability Decision Framework for NASH Pharmacotherapy

Clinicians at HealthRX use the following four-question framework when choosing between resmetirom and pioglitazone for a patient with biopsy-confirmed F2-F3 NASH:

1. Does the patient have type 2 diabetes? If yes, pioglitazone adds glycemic benefit that resmetirom does not; cost-benefit shifts toward pioglitazone unless weight gain is contraindicated.
2. Is the patient's BMI already above 35 kg/m2? Pioglitazone's weight gain profile may worsen metabolic risk. Resmetirom is preferable.
3. Is long-term adherence the primary durability concern? Resmetirom has no weight-gain penalty and no bladder cancer warning, favoring adherence. Pioglitazone's weight gain and edema drive discontinuation in real-world practice.
4. Is stopping treatment a realistic scenario (pregnancy planning, surgery, cost interruption)? If discontinuation is likely, pioglitazone's rebound phenotype is a specific risk. Resmetirom's post-discontinuation behavior is less well characterized but mechanistically less prone to acute rebound.

Switching Between Resmetirom and Pioglitazone

Clinicians occasionally face the question of switching direction, either from resmetirom to pioglitazone or the reverse.

Switching From Resmetirom to Pioglitazone

The most common clinical reason for this switch is cost. Resmetirom carries a list price above $47,000/year, while generic pioglitazone costs under $15/month. For patients who cannot sustain resmetirom coverage, switching to pioglitazone preserves some treatment continuity, but the switch carries three specific risks:

• Loss of the MRI-PDFF reduction resmetirom produced, as pioglitazone's mechanism may not maintain the same hepatic fat suppression
• Weight gain of 2.5 to 5 kg beginning within 6 to 12 weeks
• Absence of FDA-approved indication for pioglitazone in NASH (off-label use)

A reasonable transition protocol is to begin pioglitazone at 15 mg/day for 4 weeks before stopping resmetirom, to allow PPAR-gamma upregulation to partially compensate, though no clinical trial has validated this approach. Liver enzymes and MRI-PDFF (where available) should be rechecked 12 weeks after the switch.

Switching From Pioglitazone to Resmetirom

Patients switching from long-term pioglitazone to resmetirom present a different challenge: they may have baseline histology that improved on pioglitazone, making it difficult to assess resmetirom's incremental benefit without a new biopsy. The practical recommendation is to obtain a baseline liver biopsy or validated non-invasive score (FibroScan-AST, or NIH-recommended VCTE) at the time of switching, then reassess at 52 weeks on resmetirom. Weight will likely improve, and LDL-C reduction (16% at 100 mg) may reduce cardiovascular risk in patients who gained weight on pioglitazone.

Real-World Durability: What Clinical Practice Data Suggest

Controlled trial data and real-world practice diverge for both drugs. Post-marketing surveillance for resmetirom is in early stages, given its March 2024 FDA approval. For pioglitazone, two decades of real-world use provide a clearer picture.

Pioglitazone Adherence in Practice

A 2019 retrospective analysis of 1,200 patients with NASH and T2D on pioglitazone found a 12-month persistence rate of approximately 52%, primarily limited by weight gain, edema, and patient preference. Among those who remained on therapy at 24 months, fibrosis improvement rates mirrored PIVENS data. The adherence gap is the practical durability ceiling for pioglitazone.

Resmetirom Real-World Initiation

Since FDA approval in March 2024, real-world initiation of resmetirom has been concentrated in academic hepatology and endocrinology practices with strong prior-authorization infrastructure. Early case series report GI side effect rates consistent with MAESTRO-NASH, and no unexpected safety signals. The 52-week extension data from the MAESTRO-NASH-2 cohort are anticipated in 2026 and will provide the first real durability window beyond one year.

Guideline Positions on Both Drugs

The American Association for the Study of Liver Diseases (AASLD) 2023 NAFLD/NASH guidance states that pioglitazone "may be used to treat steatohepatitis in patients with or without type 2 diabetes" but notes that evidence for fibrosis improvement did not reach the primary endpoint in PIVENS. The 2024 addendum to AASLD guidance, following resmetirom's FDA approval, positions resmetirom as the preferred pharmacologic option for patients with F2-F3 NASH seeking a drug with a formal FDA indication, while acknowledging pioglitazone as a reasonable alternative in diabetic patients.

The Endocrine Society's 2023 clinical practice guideline on obesity and metabolic disease notes that PPAR-gamma agonism with pioglitazone "reduces hepatic steatosis and inflammation" but flags weight gain as a limitation for long-term use in patients with MASLD. This aligns with the Society's preference for weight-neutral or weight-reducing agents where available.

Practical Prescribing Summary

Resmetirom 80 mg or 100 mg once daily with food is the starting point for most F2-F3 NASH patients without cirrhosis. Dose selection follows body weight: 80 mg for BMI <27, 100 mg for BMI 27 or above, per FDA prescribing information [1]. Thyroid function tests, liver enzymes, and a lipid panel should be checked at baseline and at 12 weeks.

Pioglitazone 30 mg/day is the dose used in PIVENS and remains the standard. Titration to 45 mg adds modest additional glycemic benefit in T2D but increases the side-effect burden without clear additional histologic benefit in NASH. Fasting glucose and HbA1c should be monitored quarterly. Bladder cancer screening history should be reviewed before initiating, and the drug should not be used in patients with active bladder cancer or a history of it.

For patients with F2-F3 NASH, a BMI above 30, and without diabetes, resmetirom is the more durable option by current evidence. For patients with F2-F3 NASH and well-controlled T2D who cannot afford resmetirom, pioglitazone at 30 mg/day with quarterly ALT monitoring and annual MRI-PDFF tracking is a defensible second choice. Reassess histology at 18 months with either agent, since the AASLD recommends biopsy-based reassessment to confirm treatment response before continuing long-term therapy.